JP7879043B2 - インターロイキン2変異体およびその使用 - Google Patents

インターロイキン2変異体およびその使用

Info

Publication number
JP7879043B2
JP7879043B2 JP2022556114A JP2022556114A JP7879043B2 JP 7879043 B2 JP7879043 B2 JP 7879043B2 JP 2022556114 A JP2022556114 A JP 2022556114A JP 2022556114 A JP2022556114 A JP 2022556114A JP 7879043 B2 JP7879043 B2 JP 7879043B2
Authority
JP
Japan
Prior art keywords
mutant
protein
mutation
mutant protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022556114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518434A5 (cg-RX-API-DMAC10.html
JP2023518434A (ja
Inventor
カイチエ ホー
フォンケン フー
ショアイシアン チョウ
ウェイウェイ ウー
Original Assignee
フォートビタ バイオロジクス(シンガポール)プライベート リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォートビタ バイオロジクス(シンガポール)プライベート リミティド filed Critical フォートビタ バイオロジクス(シンガポール)プライベート リミティド
Publication of JP2023518434A publication Critical patent/JP2023518434A/ja
Publication of JP2023518434A5 publication Critical patent/JP2023518434A5/ja
Priority to JP2026001948A priority Critical patent/JP2026081255A/ja
Application granted granted Critical
Publication of JP7879043B2 publication Critical patent/JP7879043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022556114A 2020-03-19 2021-03-19 インターロイキン2変異体およびその使用 Active JP7879043B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026001948A JP2026081255A (ja) 2020-03-19 2026-01-08 インターロイキン2変異体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010197740.4 2020-03-19
CN202010197740 2020-03-19
CN202110266549.5 2021-03-11
CN202110266549 2021-03-11
PCT/CN2021/081840 WO2021185361A1 (zh) 2020-03-19 2021-03-19 白介素2突变体及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026001948A Division JP2026081255A (ja) 2020-03-19 2026-01-08 インターロイキン2変異体およびその使用

Publications (3)

Publication Number Publication Date
JP2023518434A JP2023518434A (ja) 2023-05-01
JP2023518434A5 JP2023518434A5 (cg-RX-API-DMAC10.html) 2024-04-02
JP7879043B2 true JP7879043B2 (ja) 2026-06-23

Family

ID=77770497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022556114A Active JP7879043B2 (ja) 2020-03-19 2021-03-19 インターロイキン2変異体およびその使用
JP2026001948A Pending JP2026081255A (ja) 2020-03-19 2026-01-08 インターロイキン2変異体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026001948A Pending JP2026081255A (ja) 2020-03-19 2026-01-08 インターロイキン2変異体およびその使用

Country Status (9)

Country Link
US (1) US20230145766A1 (cg-RX-API-DMAC10.html)
EP (1) EP4122952A4 (cg-RX-API-DMAC10.html)
JP (2) JP7879043B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220155316A (cg-RX-API-DMAC10.html)
CN (1) CN115698052A (cg-RX-API-DMAC10.html)
AU (1) AU2021239225B2 (cg-RX-API-DMAC10.html)
CA (1) CA3175717A1 (cg-RX-API-DMAC10.html)
TW (1) TWI790573B (cg-RX-API-DMAC10.html)
WO (1) WO2021185361A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
WO2021185362A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途
CN118598977A (zh) * 2020-10-18 2024-09-06 北京志道生物科技有限公司 经修饰的il-2分子及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TWI825544B (zh) 2020-12-31 2023-12-11 大陸商信達生物製藥(蘇州)有限公司 含異二聚體抗體Fc的蛋白以及其製備方法
JP7864826B2 (ja) * 2021-09-22 2026-05-25 フォートビタ バイオロジクス(シンガポール)プライベート リミティド インターロイキン2変異体およびその融合タンパク質
CN116375879A (zh) * 2021-12-16 2023-07-04 信达生物制药(苏州)有限公司 B7-h3免疫缀合物及其应用
WO2023169524A1 (zh) * 2022-03-10 2023-09-14 广东菲鹏制药股份有限公司 白细胞介素2突变体以及含有其的复合物
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
WO2023241653A1 (zh) * 2022-06-17 2023-12-21 舒泰神(北京)生物制药股份有限公司 白介素-2(il-2)突变体及其用途
WO2024008126A1 (en) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Il2 muteins and uses thereof
CN118620056A (zh) * 2023-03-09 2024-09-10 北京天广实生物技术股份有限公司 Il-2变体及其用途
KR20260008731A (ko) * 2023-03-21 2026-01-16 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 항-pd-1 및 돌연변이 il-2 면역접합체 제제
EP4739334A1 (en) * 2023-07-05 2026-05-13 Nanotein Technologies, Inc. Cell signaling complexes and uses thereof
CN117116336B (zh) * 2023-10-18 2024-01-23 深圳新锐基因科技有限公司 基于内部原子波动改善蛋白结构柔性弱点的方法和装置
IL328822A (en) * 2023-12-19 2026-08-01 Cephalon Llc Uses for attenuated IL-2 immunosuppressants
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506793A (ja) 2011-02-10 2014-03-20 ロシュ グリクアート アーゲー ミュータントインターロイキン−2ポリペプチド
WO2019246404A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN112105634B (zh) * 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
WO2021185362A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途
JP7864826B2 (ja) * 2021-09-22 2026-05-25 フォートビタ バイオロジクス(シンガポール)プライベート リミティド インターロイキン2変異体およびその融合タンパク質

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506793A (ja) 2011-02-10 2014-03-20 ロシュ グリクアート アーゲー ミュータントインターロイキン−2ポリペプチド
WO2019246404A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Interleukin-2 variants and methods of uses thereof

Also Published As

Publication number Publication date
EP4122952A1 (en) 2023-01-25
AU2021239225A1 (en) 2022-10-13
WO2021185361A1 (zh) 2021-09-23
CA3175717A1 (en) 2021-09-23
US20230145766A1 (en) 2023-05-11
TWI790573B (zh) 2023-01-21
KR20220155316A (ko) 2022-11-22
CN115698052A (zh) 2023-02-03
EP4122952A4 (en) 2024-05-29
JP2026081255A (ja) 2026-05-18
TW202144392A (zh) 2021-12-01
JP2023518434A (ja) 2023-05-01
AU2021239225B2 (en) 2024-08-15

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260611

R150 Certificate of patent or registration of utility model

Ref document number: 7879043

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150